These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?

CRISPR Therapeutics (up ~44% YTD vs S&P 500 ~18%) is being framed as a high-upside, high-risk gene‑editing play as early-stage candidates CTX310 (LDL/triglyceride reduction) and CTX320 (Lp(a) reduction) show promising data while the company remains minimally revenue-generating and unprofitable; management also expects commercial progress for approved product Casgevy in 2026. HCA Healthcare (up ~58% YTD) has beaten expectations, trades at ~16x forward EPS versus a healthcare peer average of 18.2x, and benefits from strong hospital rankings and demographic tailwinds, but faces near-term policy risk (uncertainty over extension of enhanced premium tax credits) that could affect patient demand.

Analysis

Market structure: Clinical-readout-driven small-cap biotech (CRSP) benefits from positive binary events; large hospital operators (HCA) benefit from scale, payer relationships and aging demographics. Positive CTX310/CTX320 data would reprice CRSP's expected cash flows and attract M&A interest, while adverse policy moves (insurance premium tax-credit changes) would shift demand away from elective hospital services and pressure utilization. Cross-asset: a biotech risk-on run raises equity vols and squeezes short-dated puts, while negative clinical news would widen credit spreads in small-cap biotech financings and push investors into defensive hospital equities and healthcare MLP/REITs.

Risk assessment: Tail risks include an FDA clinical hold or safety signal at CRSP (low probability, >60% downside on headline failure) and a federal policy rollback in H1–H2 2026 reducing insured volumes by an estimated 1–3% (2–6% EPS hit for some hospitals). Near-term (days–weeks) volatility will be dominated by option markets and newsflow; medium-term (3–12 months) by trial readouts and policy decisions; long-term (2–5 years) by commercial execution of Casgevy and pipeline launches. Hidden dependencies: CRSP’s valuation is levered to partner financing and equity markets for follow-on funding; HCA’s margins depend on payer mix shifts and outpatient migration.

Trade implications: Tactical postures: small, asymmetric exposure to CRSP (binary upside) and core holding in HCA (value/defensive). Use option structures to buy convexity on CRSP and sell premium on HCA. Rotate 2–4% portfolio weight from broad healthcare ETFs into select operators with secular advantages and from floating-rate hospital REITs into high-quality hospital equities if credit spreads compress.

Contrarian angles: Consensus underestimates commercialization risk for Casgevy (execution, pricing) and overestimates immediate upside for CTX programs — the market often overpays pre-readout for gene-editing optionality. Conversely, implied vol may overprice downside in CRSP after recent run; buying calibrated long-dated call spreads can capture asymmetric upside while capping loss. Historical parallels: gene-editing winners often saw 2x+ moves on Phase 2 success and near-total write-downs on safety failures; position sizing must reflect that skew.

Key Decisions for Investors

• Establish a tactical 1–1.5% long position in CRSP (ticker CRSP) immediately; if CTX310/CTX320 Phase readouts due H1–H2 2026 are positive, scale to 3% total. Size as risk capital only and cap aggregate biotech exposure to <5% of portfolio.
• Implement defined-risk options on CRSP: buy 12–18 month LEAP 25–35% OTM call spreads sized to 0.5–1% of portfolio notional (maximum loss = premium). Prefer spreads to naked calls to limit downside if trial fails.
• Initiate a 2–3% core long in HCA (ticker HCA) for value/defensive exposure; enhance yield by selling 3–6 month covered calls at +15–20% strike over current price. Reduce exposure if forward P/E compresses below 14x or if insured volumes fall by >2% after a policy decision.
• Pair trade: long CRSP vs short XBI (SPDR S&P Biotech ETF) sized 1:1 notional to isolate idiosyncratic upside; rebalance after each major readout. This hedges market beta while retaining CRSP's binary upside.
• Hedge policy tail risk: buy 3–6 month 5% OTM put protection on HCA sized 0.5% of portfolio ahead of any federal premium tax-credit decision expected by mid-2026; unwind if decision favors continued subsidy or if put prices compress >30%.